November 30, 2009
Chuikyo's Expert Subcommittee on NHI Drug Pricing Affairs has decided to review the current new drug pricing rule in response to the criticism that the treatment for Parkinson's disease Trerief (zonisamide) and the treatment for schizophrenia Risperdal Consta (risperidone) were...read more